Oncology Clinical Research Associate II – Madrid

Syneos Health; España; Presencial; EUR 35.000 - 52.000; Jornada completa

Descripción de la vacante

Syneos Health is seeking a CRA II in Madrid to support oncology clinical trials (lung) at Sponsor dedicated. You will perform site qualification, initiation, monitoring, and close-out visits, on-site or remotely, ensuring ICH-GCP compliance and proper data capture.

Join a global team delivering innovative cancer therapies and maintaining TMF integrity while collaborating closely with investigators to advance patient progress.

Formación

Responsabilidades

• Performs site qualification, site initiation, interim monitoring, site management activities and close-out visits (performed on-site or remotely) ensuring regulatory, ICH-GCP and/or Good Pharmacoepidemiology Practice (GPP) and protocol compliance.
• Verifies the process of obtaining informed consent has been adequately performed and documented for each subject/patient, as required/appropriate.
• Assesses site processes. Conducts Source Document Review of appropriate site source documents and medical records. Verifies required clinical data entered in the case report form (CRF) is accurate and complete.
• Applies query resolution techniques remotely and on site, and provides guidance to site staff as necessary, driving query resolution to closure within agreed timelines.
• Routinely reviews the Investigator Site File (ISF) for accuracy, timeliness and completeness. Reconciles contents of the ISF with the Trial Master File (TMF).
• May act as primary liaison with study site personnel, or in collaboration

Descripción del empleo

Syneos Health is seeking a CRA II in Madrid to support oncology clinical trials (lung) at Sponsor dedicated. You will perform site qualification, initiation, monitoring, and close-out visits, on-site or remotely, ensuring ICH-GCP compliance and proper data capture.

Join a global team delivering innovative cancer therapies and maintaining TMF integrity while collaborating closely with investigators to advance patient progress.